RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
Total raised: $110M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.04.2025 | Series A | $110M | - |
Mentions in press and media 3
| Date | Title | Description |
| 08.04.2025 | RayThera: $110 Million (Series A) Raised For Developing Small Molecule Therapies In Immunology | RayThera—a recently founded biotechnology company focused on discovering and developing small-molecule therapies in immunology—announced that it has completed its Series A financing, raising a total of $110 million. The funding round was co... |
| 07.04.2025 | RayThera Raises $110M in Series A Financing | RayThera, a San Diego, CA-based biotechnology company currently focused on discovering and developing small molecule therapies in immunology, raised $110M in Series A funding. The round was led by Foresite Capital and OrbiMed Advisors, with... |
| - | RayThera | “RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.”... |